Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

The injectable production specialist has snapped up a 65-acre property with more than 300,000 square feet of usable space to ...

The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the ...

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...